CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Vir Biotechnology's Hepatitis Delta Therapy Meets Primary Endpoint in Phase 3 Trial

By Public Technologies
  • Vir Biotechnology's elebsiran-tobevibart combination met the primary endpoint in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis delta.
  • Monthly treatment achieved undetectable virus with normalized liver enzymes; the regimen was well tolerated, with no treatment interruptions or discontinuations.
  • Results were presented at the American Association for the Study of Liver Diseases' The Liver Meeting 2026 in Denver.
  • Additional pivotal trial results are expected in the first quarter of 2027, supporting a planned FDA submission in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261108631000) on November 08, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk